697 A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed/refractory small cell lung cancer (SCLC)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.